Current European Studies of Sentinel Lymph Node Biopsy for Breast Cancer  by Sandelin, Kerstin
ASIAN JOURNAL OF SURGERY  VOL 27 • NO 4 • OCTOBER 2004 291
070/2001
Symposium: Breast Cancer
Current European Studies of Sentinel Lymph Node
Biopsy for Breast Cancer
Kerstin Sandelin, Department of Surgical Sciences, Karolinska University Hospital, Stockholm, Sweden.
The paradigm shift in the assessment of the axilla in breast surgery has evoked specific clinical issues. In a
population where breast cancer is diagnosed early and service screening mammography is applied, the chance for
a woman to be free of lymph node metastases is approximately 60%. Currently, there are three ongoing and one
published randomized series on sentinel node lymphadenectomy in Europe, comprising more than 100 patients.
These studies address the important issues of morbidity, quality of life and long-term outcome measures such as
survival and recurrence. [Asian J Surg 2004;27(4):291–3]
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Introduction
Publications on sentinel lymph node biopsy (SLNB) for breast
cancer have concluded that it is feasible and accurate after
appropriate training. There is still variability regarding tech-
niques and methods for localizing the sentinel node(s), but
these facts have not substantially altered the results in the
larger published series.
SLNB was quickly adopted in the 1990s and, at the first
Sentinel Node Congress in Amsterdam in 1998, it became
clear that after a learning phase, many centres began adopting
SLNB as part of clinical practice.
To the author’s knowledge, there are very few national
studies that have explored the diagnostic and clinical path-
ways with SLNB in a sequential manner. On the contrary,
many breast centres have recorded and published their experi-
ence in the various steps of SLNB. Denmark has a national
database for breast cancer management, the Danish Breast
Cancer Cooperative Study Group (DBCG). The guidelines
that describe indications for SLNB and auditing are clearly
stated.1 To date, most centres that perform breast surgery in
Denmark offer SLNB and, thus, report to the DBCG. There is,
however, no national trial ongoing.
In Sweden, the introduction of SLNB and the formation
of the Swedish Breast Surgery Section almost coincided, and
since 1997, trials on feasibility, audit and validation have
followed. More or less complete coverage of all SLNB in
Sweden is registered (L. Bergkvist, personal communication,
December 2003). Centres that meet the prerequisites with
documented and successful learning experience have partici-
pated in a study where 2,000 selected patients underwent
SLNB with or without axillary clearance for assessment of
axillary recurrence. From the three studies performed so
far, the detection rate increased after the audit phase from 94%
to 97% (L. Bergkvist, personal communication, December
2003).2
In the UK, only centres that have enrolled in the national
randomized trial perform SLNB.
The different specific variables that have been the focus of
the larger European trials have included imaging techniques,
histopathological assessment of sentinel nodes, assessment
and consequences of micrometastases, axillary morbidity,
quality of life, therapeutic consequences of a positive sentinel
node, and health economics.3–9 The European Working Group
for Breast Screening Pathology recently published a review on
current data and recommendations for guidelines.10
This review will focus on the work that has emerged from
European centres that have conducted randomized trials. At
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the time of writing, a MEDLINE search was made for ran-
domized clinical trials published in English (between 1997
and September 2003). There were 10 hits, three of which were
European. Two of these studies dealt with labelling and injec-
tion techniques, comprised 20 and 80 patients, and therefore
will not be mentioned in detail.11,12 The third study was a
validation study of SLNB versus routine axillary dissection.13
The other cited references have been selected to be representa-
tive of the current ongoing research in the field.
There are currently three ongoing randomized European
multicentre trials.
European randomized trials
ALMANAC
To date, SLNB in the UK is limited to a few centres as the
method has not been approved as standard treatment. The
Axillary Lymphatic Mapping Against Axillary Clearance
(ALMANAC) trial is funded by the UK Medical Research
Council.14 It is a multicentre trial that consists of two phases,
one audit phase where organized training occurs and where
identification of the sentinel node should be 90% and the false-
negative rate should be less than 5% after 40 cases have been
performed. Once these requirements are fulfilled, centres can
join the randomized trial, which includes all patients with
planned axillary surgery to either have SLNB or standard
treatment. The histopathological diagnosis of the sentinel
node is made from paraffin sections. The primary endpoints of
the study are axillary morbidity and quality of life, but the
study also compares health economic issues between the dif-
ferent procedures. With longer follow-up, the study will also
address the issue of axillary recurrence.
SLNB versus routine axillary dissection in breast cancer
This study involved a single institution. The primary endpoint
of the study was the predictive status of the sentinel node
compared to axillary status in patients who underwent full
axillary clearance after SLNB. Secondary endpoints were qual-
ity of life, axillary recurrence and survival. The trial included
low-risk patients (i.e. patients with tumours < 2 cm) who
were eligible for breast conservation therapy. Of 649 eligible
patients, 516 were included. The histopathological assess-
ment was extremely thorough and included frozen-section
analysis with approximately 60 sections per node at intervals
of 100 μm. The results showed an overall accuracy of 96.9%.13
The false-negative rate was 8.8%. With 4 years’ follow-up, no
axillary recurrence had occurred.
Micrometastases in sentinel nodes (IBCSG 23-01)
In this multicentre trial, the prognostic significance of micro-
metastases will be assessed, as this issue remains highly
controversial. More than 60% of low-risk patients are free of
axillary metastases. A labour-intensive technique in which
numerous lymph nodes are examined shows that the actu-
al rate of micrometastases increases. The clinical impor-
tance of micrometastatic spread in the sentinel-node setting
is unknown and different views prevail. The endpoints of the
current study are disease-free survival and overall survival.
Patients with unifocal breast cancer less than 3 cm in
greatest diameter with proven micrometastases after SLNB are
randomized to proceed with axillary clearance or observation.
The study implies meticulous histopathological examination
of the sentinel node with the technique described above. Some
1,900 patients are needed for evaluation of the endpoints.15
AMAROS
The After Mapping of the Axilla Radiotherapy Or Surgery
(AMAROS) study is a multicentre international phase III trial
to assess treatment of the axilla.16 Randomized patients with
tumours of less than 3 cm will undergo SLNB. Patients with
negative SLNB will be observed without further treatment,
whereas patients with positive SLNB will either undergo axil-
lary lymphadenectomy or receive radiation to the axilla. The
principal aim of the trial is to assess morbidity between the
different treatments. A secondary endpoint will be morbidity
after SLNB only. To answer these questions, some 3,400 pa-
tients should be included. Possible reasons for the rather
modest accrual are the study design that combines surgery and
radiation therapy. The radiotherapy guidelines were studied
in a trial where participating centres were asked to provide a
radiotherapy plan according to the AMAROS study protocol.
The findings led to enhanced protocol compliance and several
adjustments were made by the participating centres.17
Conclusions
SLNB has gained widespread popularity in Europe, although
it is not yet a recognized treatment in the UK. In three
Scandinavian countries, there are national guidelines and
auditing of the procedure. There are currently three randomized
trials published in the English literature: two multicentre
studies and one single-institution study. These studies, in
combination with other randomized trials outside Europe,
will provide evidence-based information that will serve as
guidelines for modern breast cancer treatment.
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